This is a preview of subscription content, log in via an institution to check access.
Notes
The study was sponsored by Vertex Pharmaceuticals Incorporated.
Reference
Vera-Llonch M, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Alimentary Pharmacology and Therapeutics : 3 Jun 2013. Available from: URL: http://dx.doi.org/10.1111/apt.12354
Rights and permissions
About this article
Cite this article
Better QOL with response-guided telaprevir in chronic HCV. PharmacoEcon Outcomes News 681, 10 (2013). https://doi.org/10.1007/s40274-013-0521-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0521-4